Cargando…

HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species

BACKGROUND: The production of recombinant monoclonal antibodies in mammalian cell culture is of high priority in research and medical fields. A critical step in this process is the isolation of the antigen-binding domain sequences of antibodies possessing the desired properties. Many different techn...

Descripción completa

Detalles Bibliográficos
Autores principales: Kivi, Gaily, Teesalu, Kaupo, Parik, Jüri, Kontkar, Elen, Ustav, Mart, Noodla, Liis, Männik, Andres
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706699/
https://www.ncbi.nlm.nih.gov/pubmed/26747451
http://dx.doi.org/10.1186/s12896-016-0232-6
_version_ 1782409205490122752
author Kivi, Gaily
Teesalu, Kaupo
Parik, Jüri
Kontkar, Elen
Ustav, Mart
Noodla, Liis
Ustav, Mart
Männik, Andres
author_facet Kivi, Gaily
Teesalu, Kaupo
Parik, Jüri
Kontkar, Elen
Ustav, Mart
Noodla, Liis
Ustav, Mart
Männik, Andres
author_sort Kivi, Gaily
collection PubMed
description BACKGROUND: The production of recombinant monoclonal antibodies in mammalian cell culture is of high priority in research and medical fields. A critical step in this process is the isolation of the antigen-binding domain sequences of antibodies possessing the desired properties. Many different techniques have been described to achieve this goal, but all have shortcomings; most techniques have problems with robustness, are time-consuming and costly, or have complications in the transfer from isolation to production phase. Here, we report a novel HybriFree technology for the development of monoclonal antibodies from different species that is robust, rapid, inexpensive and flexible and can be used for the subsequent production of antibodies in mammalian cell factories. RESULTS: HybriFree technology is illustrated herein via detailed examples of isolating mouse, rabbit and chicken monoclonal antibody sequences from immunized animals. Starting from crude spleen samples, antigen capturing of specific B-cells is performed initially. cDNA of antibody variable domains is amplified from the captured cells and used a source material for simple and rapid restriction/ligation free cloning of expression vector library in order to produce scFv-Fc or intact IgG antibodies. The vectors can be directly used for screening purposes as well as for the subsequent production of the developed monoclonal antibodies in mammalian cell culture. The antibodies isolated by the method have been shown to be functional in different immunoassays, including ELISA, immunofluorescence and Western blot. In addition, we demonstrate that by using a modified method including a negative selection step, we can isolate specific antibodies targeting the desired epitope and eliminate antibodies directed to undesired off-targets. CONCLUSIONS: HybriFree can be used for the reliable development of monoclonal antibodies and their subsequent production in mammalian cells. This simple protocol requires neither the culturing of B-cells nor single-cell manipulations, and only standard molecular biology laboratory equipment is needed. In principle, the method is applicable to any species for which antibody cDNA sequence information is available. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12896-016-0232-6) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4706699
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-47066992016-01-10 HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species Kivi, Gaily Teesalu, Kaupo Parik, Jüri Kontkar, Elen Ustav, Mart Noodla, Liis Ustav, Mart Männik, Andres BMC Biotechnol Methodology Article BACKGROUND: The production of recombinant monoclonal antibodies in mammalian cell culture is of high priority in research and medical fields. A critical step in this process is the isolation of the antigen-binding domain sequences of antibodies possessing the desired properties. Many different techniques have been described to achieve this goal, but all have shortcomings; most techniques have problems with robustness, are time-consuming and costly, or have complications in the transfer from isolation to production phase. Here, we report a novel HybriFree technology for the development of monoclonal antibodies from different species that is robust, rapid, inexpensive and flexible and can be used for the subsequent production of antibodies in mammalian cell factories. RESULTS: HybriFree technology is illustrated herein via detailed examples of isolating mouse, rabbit and chicken monoclonal antibody sequences from immunized animals. Starting from crude spleen samples, antigen capturing of specific B-cells is performed initially. cDNA of antibody variable domains is amplified from the captured cells and used a source material for simple and rapid restriction/ligation free cloning of expression vector library in order to produce scFv-Fc or intact IgG antibodies. The vectors can be directly used for screening purposes as well as for the subsequent production of the developed monoclonal antibodies in mammalian cell culture. The antibodies isolated by the method have been shown to be functional in different immunoassays, including ELISA, immunofluorescence and Western blot. In addition, we demonstrate that by using a modified method including a negative selection step, we can isolate specific antibodies targeting the desired epitope and eliminate antibodies directed to undesired off-targets. CONCLUSIONS: HybriFree can be used for the reliable development of monoclonal antibodies and their subsequent production in mammalian cells. This simple protocol requires neither the culturing of B-cells nor single-cell manipulations, and only standard molecular biology laboratory equipment is needed. In principle, the method is applicable to any species for which antibody cDNA sequence information is available. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12896-016-0232-6) contains supplementary material, which is available to authorized users. BioMed Central 2016-01-08 /pmc/articles/PMC4706699/ /pubmed/26747451 http://dx.doi.org/10.1186/s12896-016-0232-6 Text en © Kivi et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Methodology Article
Kivi, Gaily
Teesalu, Kaupo
Parik, Jüri
Kontkar, Elen
Ustav, Mart
Noodla, Liis
Ustav, Mart
Männik, Andres
HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species
title HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species
title_full HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species
title_fullStr HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species
title_full_unstemmed HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species
title_short HybriFree: a robust and rapid method for the development of monoclonal antibodies from different host species
title_sort hybrifree: a robust and rapid method for the development of monoclonal antibodies from different host species
topic Methodology Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706699/
https://www.ncbi.nlm.nih.gov/pubmed/26747451
http://dx.doi.org/10.1186/s12896-016-0232-6
work_keys_str_mv AT kivigaily hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies
AT teesalukaupo hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies
AT parikjuri hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies
AT kontkarelen hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies
AT ustavmart hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies
AT noodlaliis hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies
AT ustavmart hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies
AT mannikandres hybrifreearobustandrapidmethodforthedevelopmentofmonoclonalantibodiesfromdifferenthostspecies